Comparing the current results to its competitors, Viatris Inc reported Revenue increase in the 2 quarter 2026 by 4.88 % year on year. The revenue growth was below Viatris Inc 's competitors' average revenue growth of 12.43 %, achieved in the same quarter.
Viatris Inc , slower than the average decrease reported by the company's competitors of -4.6 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -4.6 %
Overall company revenue, grew less, than total company revenues, at 4.88 % and company approximately market share, declined to 2.45 %. << More on VTRS Market Share.
*Market share is calculated based on total revenue.
June 2, 2025
The Law of the Land: Viatris Inc. Investors Urged to Stand Up for JusticeIn a striking turn of events, investors of Viatris Inc. (NASDAQ: VTRS) are being called to action as Bronstein, Gewirtz and Grossman LLC, a renowned law firm, initiates a class action lawsuit against the pharmaceutical company and its officers. This announcement on June 2, 2025, beckons those who have suffered substantial losses in their investments to join what promises to be a pivotal moment for accountability in the corporate sphere.Viatris, formed through the merger of Mylan and Upjohn, has recently come under scrutiny as its stock performance lags woefully behind market expectations. While the overall market has enjoyed a robust 9...
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pharming Group N.V. operates on a business model focused on the development, production, and commercialization of innovative therapeutic products for the treatment of rare diseases and unmet medical needs. The company primarily generates revenue by selling its approved products in various geographic markets and through strategic collaborations with pharmaceutical partners. Pharming Group N.V. also engages in research and development activities to expand its product pipeline and explore potential new treatments.
Sources:
Viatris Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Viatris Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
